Tesla's shares were down early Monday after having fallen 0.5% to $187.9 in the final session of the last week.
The stock move came after The Wall Street Journal reported over the weekend that Tesla CEO Elon Musk took drugs with some Tesla board members, citing people who have witnessed the drug use and others with knowledge of it.
It said the volume of drug use by Musk and with board members has become concerning, according to some of these people. Barron's contacted Tesla for comment early Monday. Musk and his lawyer, Alex Spiro, didn't respond to requests for comment, when The Wall Street Journal said it had approached them.
Last week, in separate news, a Delaware court voided Musk's pay package, which awarded him some 300 million options that vested based on hitting performance milestones, according to multiple media reports. The ruling, which MarketWatch said essentially nullifies Musk's $55.8 billion pay package, could have wide implications for the rest of corporate America. Musk is considering moving the legal incorporation of Tesla from Delaware to Texas.
Tesla stock was 1.4% lower in premarket trading Monday. Nasdaq Composite futures were down 0.1%. Tesla shares have fallen 21.9% over the past month while the S&P 500 and Nasdaq Composite have risen 4.1% and 7.6% respectively.
Tesla was trading well off its 52-week high of $299.29, which the company reached last summer.
The stock was outperformed by some of its competitors Monday as Lucid rose 1.2% to $3.35, NIO rose1.3% to $5.61, but BYD was down by 0.6% in Hong Kong trading. General Motors fell 0.2% to $38.83.
Tesla's trading volume of 110.6 million shares was 6.5 million below its 65-day average volume of 117.1 million at Friday's close.